Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B_West China Medical Journal

Authors：

 WangLin , ZhangHong , GaoFeng ,  FanHezhang

The Third Ward, Chengdu Public Health and Medical Center, Chengdu, Sichuan 610061, P. R. China;

Corresponding?author：

FanHezhang, Email: fanzhangli@sina.com

Keywords：

Chronic hepatitis B; Treatment; Gankang granule; Entecavir

DOI：

10.7507/1002-0179.201600188

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical efficacy of combined therapy of Gankang Granule and Entecavir for patients with chronic hepatitis B. Methods A total of 118 patients with chronic hepatitis B treated between January 2012 and January 2013 were randomly divided into treatment group (n=59) and control group (n=59). Patients in the treatment group were treated with Gankang Granule and Entecavir, while those in the control group were treated with Entecavir alone. Results Before treatment, there was no significant difference between the two groups in such liver fibrosis evaluation indexes as hyaluronic acid (HA), laminin (LN), procollagenⅢ(PCⅢ), and collegen typeⅣ(CⅣ) (P > 0.05). After treatment, the two groups had significant differences in HA, LN, PCⅢ, and CⅣ(P < 0.05). After 48 weeks of treatment, the alanine aminotransferase recovery rate was significantly different between the two groups (P < 0.05); but there was no significant difference in hepatitis B virus DNA negative conversion rate, hepatitis B e antigen negative conversion rate and hepatitis B e antibody seroconversion rate (P > 0.05). Forty-eight weeks after treatment began, 45 patients underwent liver biopsy which showed that liver fibrosis alleviation was significantly better in the treatment group than the control group (P < 0.05). Conclusions Gankang granule combined with antiviral drug Entecavir for chronic hepatitis B is better in protecting the liver and alleviating hepatic fibrosis than the sole Entecavir. The combined method is worthy of being promoted.

Citation： WangLin, ZhangHong, GaoFeng, FanHezhang. Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B. West China Medical Journal, 2016, 31(4): 688-691. doi: 10.7507/1002-0179.201600188 Copy

1.	?Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444.
2.	Lok AS. Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(4): 199-200.
3.	曾婷, 謝逸欣, 馬麗. 恩替卡韋的藥理毒理學研究[J]. 河北醫學, 2012, 18(10): 1421-1423.
4.	中華醫學會肝病學分會, 中華醫學會感染病學分會. 慢性乙型肝炎防治指南(2010年版)[J]. 胃腸病學, 2011, 19(6): 351-366.
5.	中華醫學會傳染病與寄生蟲病學會, 中華醫學會肝病學分會. 病毒性肝炎防治方案[J]. 中華肝臟病雜志, 2000, 8(6): 324-329.
6.	World Health Organization. Guidelines for the Prevention. Care and treatement of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
7.	李筠, 湯勃. 中藥對慢性乙肝病毒復制的影響[J]. 世界華人消化雜志, 2000, 8(8): 945-946.
8.	何義華, 潘志恒, 李林, 等. 中藥辨證治療中重度慢性乙肝臨床療效對照分析[J]. 世界華人消化雜志, 2007, 15(28): 3006-3010.
9.	劉小明, 邱春艷, 丁新華, 等. 七五靈散調理慢性乙肝后40例[J]. 中國中醫藥現代遠程教育, 2013, 11(24): 33.
10.	賀勁松, 周大橋, 童光東, 等. 補腎健脾膠囊治療慢性乙肝病毒攜帶者的隨機雙盲實驗[J]. 中國實驗方劑學雜志, 2010, 16(6): 246-249.
11.	陸寧, 趙湖珊. 苦參素聯合中藥治療慢性乙肝療效觀察[J]. 遼寧中醫雜志, 2003, 30(1): 38-39.
12.	張開生, 王清霞. 丹參注射液聯合復方甘草酸苷治療慢性乙肝療效觀察[J]. 中國社區醫師: 醫學專業, 2010, 12(24): 120.
13.	唐茂華, 陳積, 饒麗萍. 恩替卡韋、阿德福韋、拉米夫定治療慢性乙型肝炎的療效比較[J]. 廣東醫學院學報, 2012, 30(2): 156-158.
14.	徐道振. 病毒性肝炎臨床實踐[M]. 北京: 人民衛生出版社, 2006: 335.
15.	Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475.

1. ?Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444.
2. Lok AS. Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(4): 199-200.
3. 曾婷, 謝逸欣, 馬麗. 恩替卡韋的藥理毒理學研究[J]. 河北醫學, 2012, 18(10): 1421-1423.
4. 中華醫學會肝病學分會, 中華醫學會感染病學分會. 慢性乙型肝炎防治指南(2010年版)[J]. 胃腸病學, 2011, 19(6): 351-366.
5. 中華醫學會傳染病與寄生蟲病學會, 中華醫學會肝病學分會. 病毒性肝炎防治方案[J]. 中華肝臟病雜志, 2000, 8(6): 324-329.
6. World Health Organization. Guidelines for the Prevention. Care and treatement of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
7. 李筠, 湯勃. 中藥對慢性乙肝病毒復制的影響[J]. 世界華人消化雜志, 2000, 8(8): 945-946.
8. 何義華, 潘志恒, 李林, 等. 中藥辨證治療中重度慢性乙肝臨床療效對照分析[J]. 世界華人消化雜志, 2007, 15(28): 3006-3010.
9. 劉小明, 邱春艷, 丁新華, 等. 七五靈散調理慢性乙肝后40例[J]. 中國中醫藥現代遠程教育, 2013, 11(24): 33.
10. 賀勁松, 周大橋, 童光東, 等. 補腎健脾膠囊治療慢性乙肝病毒攜帶者的隨機雙盲實驗[J]. 中國實驗方劑學雜志, 2010, 16(6): 246-249.
11. 陸寧, 趙湖珊. 苦參素聯合中藥治療慢性乙肝療效觀察[J]. 遼寧中醫雜志, 2003, 30(1): 38-39.
12. 張開生, 王清霞. 丹參注射液聯合復方甘草酸苷治療慢性乙肝療效觀察[J]. 中國社區醫師: 醫學專業, 2010, 12(24): 120.
13. 唐茂華, 陳積, 饒麗萍. 恩替卡韋、阿德福韋、拉米夫定治療慢性乙型肝炎的療效比較[J]. 廣東醫學院學報, 2012, 30(2): 156-158.
14. 徐道振. 病毒性肝炎臨床實踐[M]. 北京: 人民衛生出版社, 2006: 335.
15. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475.

West China Medical Journal

Application of Combined Therapy of Gankang Granule and Entecavir for Patients with Chronic Hepatitis B

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content